{"nctId":"NCT01667731","briefTitle":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults","startDateStruct":{"date":"2012-07"},"conditions":["Hepatitis C","Human Immunodeficiency Virus"],"count":224,"armGroups":[{"label":"SOF+RBV 12 Weeks (GT 2/3, TN)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV 24 Weeks (GT 2/3, TE)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV 24 Weeks (GT 1, TN)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]}],"interventions":[{"name":"SOF","otherNames":["GS-7977","PSI-7977","Sovaldi®"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Male or female, age ≥ 18 years with chronic HCV and HIV-1 infection\n* HCV RNA \\> 1 x 10\\^4 IU/mL at screening\n* Infection with HCV genotype 1, 2 or 3 as determined at screening\n* HIV-1 infection confirmed with positive ELISA or Western blot at screening\n* Medical records must be sufficient to be categorized on interferon (IFN) eligibility or prior treatment history with PEG/RBV.\n* Confirmation of chronic HCV infection\n* Ability to determine presence/absence of cirrhosis.\n* HIV antiretroviral therapy (ARV) criteria of one of the following:\n\n  * ARV untreated with a CD4 T-cell count \\> 500 cells/mm\\^3\n  * On a stable, protocol-approved, ARV for \\> 8 weeks prior to screening with a CD4 T-cell count \\> 200 cells/mm\\^3 and a documented undetectable plasma HIV-1 RNA level for ≥ 8 weeks preceding the screening visit\n* Approved HIV antiretroviral medications based on drug interaction studies\n* Not been treated with any investigational drug or device within 30 days of the screening visit\n* Females if confirmed that she is not pregnant or nursing of non-childbearing potential or of childbearing potential but has a negative serum pregnancy test at screening and agrees to use protocol approved method of birth control from screening through 6 months after the last dose of RBV\n* Males who agree to consistently and correctly use a condom while their female partner agrees to use protocol approved method of birth control from screening through 7 months after the last dose of RBV\n* Must be of generally good health as determined by the investigator.\n* Liver imaging within 6 months of baseline/Day 1 is required in cirrhotic patients only, to exclude hepatocellular carcinoma (HCC)\n\nExclusion Criteria:\n\n* Non-genotype 1/2/3 or mixed genotype at screening\n* Genotype 1 with prior treatment for HCV\n* Poor control with ARV regimen\n* Prior exposure to a direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase\n* Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson's disease, α1 antitrypsin deficiency, cholangitis)\n* A new AIDS-defining condition diagnosed within 30 days prior to screening\n* Active, serious infection (other than HIV or HCV) requiring parenteral antibiotics, antivirals or antifungals within 30 days prior to baseline\n* Infection with hepatitis B virus (HBV)\n* Contraindication to RBV therapy\n* Chronic use of systemically administered immunosuppressive agents (eg, prednisone equivalent \\> 10 mg/day)\n* History of solid organ transplantation or malignancy diagnosed or treated within 5 years\n* Current or prior history of clinical hepatic decompensation or other significant gastrointestinal disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"91.7","spread":null},{"groupId":"OG003","value":"94.1","spread":null},{"groupId":"OG004","value":"76.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)","description":"The percentage of participants discontinuing any study drug due to an adverse event was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"71.4","spread":null},{"groupId":"OG002","value":"95.8","spread":null},{"groupId":"OG003","value":"94.1","spread":null},{"groupId":"OG004","value":"80.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"91.7","spread":null},{"groupId":"OG003","value":"88.2","spread":null},{"groupId":"OG004","value":"75.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 1","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.69","spread":"0.471"},{"groupId":"OG001","value":"-4.52","spread":"0.464"},{"groupId":"OG002","value":"-4.63","spread":"0.680"},{"groupId":"OG003","value":"-4.78","spread":"0.354"},{"groupId":"OG004","value":"-4.42","spread":"0.958"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 2","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.11","spread":"0.574"},{"groupId":"OG001","value":"-4.84","spread":"0.579"},{"groupId":"OG002","value":"-5.15","spread":"0.813"},{"groupId":"OG003","value":"-5.06","spread":"0.467"},{"groupId":"OG004","value":"-5.00","spread":"0.829"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 4","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.04","spread":"0.710"},{"groupId":"OG001","value":"-4.86","spread":"0.602"},{"groupId":"OG002","value":"-5.16","spread":"0.820"},{"groupId":"OG003","value":"-5.06","spread":"0.467"},{"groupId":"OG004","value":"-5.12","spread":"0.957"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 6","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.593"},{"groupId":"OG001","value":"-4.86","spread":"0.602"},{"groupId":"OG002","value":"-5.16","spread":"0.820"},{"groupId":"OG003","value":"-5.06","spread":"0.467"},{"groupId":"OG004","value":"-5.20","spread":"0.785"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 8","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.13","spread":"0.593"},{"groupId":"OG001","value":"-4.83","spread":"0.589"},{"groupId":"OG002","value":"-5.16","spread":"0.820"},{"groupId":"OG003","value":"-5.06","spread":"0.467"},{"groupId":"OG004","value":"-5.20","spread":"0.785"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as:\n\n1. Viral breakthrough: HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment, confirmed with 2 consecutive values (second confirmation value may have been posttreatment) or with a last available on-treatment measurement and no subsequent follow-up values, or\n2. Viral rebound: \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values (second confirmation value may have been posttreatment) or with a last available on-treatment measurement and no subsequent follow-up values, or\n3. Nonresponse: HCV RNA persistently ≥ LLOQ through 8 weeks of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Viral Relapse","description":"Viral relapse was defined as having achieved undetectable HCV RNA levels (HCV RNA \\< LLOQ) at end of treatment, but did not achieve an SVR.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"4.2","spread":null},{"groupId":"OG003","value":"5.9","spread":null},{"groupId":"OG004","value":"22.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":68},"commonTop":["Fatigue","Insomnia","Nausea","Headache","Upper respiratory tract infection"]}}}